| 1 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. Ca Cancer J Clin, 2018, 68(6): 394-424
|
| 2 |
Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(3): 177-193.
|
| 3 |
王光彦, 李海燕, 杨思俊, 等. 肿瘤标志物的研究发展及临床应用 [J]. 中国保健营养, 2017, 27(9): 429.
|
| 4 |
You W, Yan L, Cai Z, et al. Clinical significances of positive postoperative serum CEA and post-preoperative CEA increment in stage II and III colorectal cancer: a multicenter retrospective study [J]. Front Oncol, 2020, 10: 671.
|
| 5 |
Hermunen K, Soveri LM, Boisen MK, et al. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer [J]. Acta Oncol, 2020, 59(12): 1416-1423.
|
| 6 |
Peltonen R, Gramkow MH, Dehlendorff C, et al. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases [J]. PLoS ONE, 2020, 15(8): e0236569.
|
| 7 |
Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma [J]. Cancer, 2006, 106(7): 1624-1633.
|
| 8 |
Min YL, Gong YX, Zhu PW, et al. CEA as a risk factor in predicting ocular metastasis from colorectal cancer [J]. J Cancer, 2020, 11(1): 51-56.
|
| 9 |
Lu Z, Peng J, Wang Z, et al. High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection [J]. Med Oncol, 2016, 33(11): 121.
|
| 10 |
Stiksma J, Grootendorst DC, van der Linden PW. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer [J]. Clin Colorectal Cancer, 2014, 13(4): 239-244.
|
| 11 |
Okamura R, Hasegawa S, Hida K, et al. Japanese study group for postoperative follow-up of colorectal cancer. The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery [J]. Int J Clin Oncol, 2017, 22(1): 96-101.
|
| 12 |
尚永明, 陈群, 李新明. 血清CEA、CA19-9及CA72-4联合检测预测转移性直肠癌患者化疗后预后的价值分析 [J]. 临床和实验医学杂志, 2018, 267(11): 65-67.
|
| 13 |
姜涛. 胃肠肿瘤标志物诊断大肠癌的检验医学研究 [J/OL]. 临床检验杂志(电子版), 2018, 7(1): 32-33.
|
| 14 |
Zhong W, Yu Z, Zhan J, et al. Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer [J]. Pathol Oncol Res, 2015, 21(1): 83-95.
|
| 15 |
Bahrami A, Hesari AR, Khazaei M, et al. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer [J]. J Cell Physiol, 2018, 233(3): 2162-2169.
|
| 16 |
Afrăsânie VA, Marinca MV, Alexa-Stratulat T, et al. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer-practical implications for the clinician [J]. Radiol Oncol, 2019, 53(3): 265-274.
|
| 17 |
Rui Y, Wang C, Zhou Z, et al. K-Ras mutation and prognosis of colorectal cancer: a meta-analysis [J]. Hepatogastroenterology, 2015, 62(137): 19-24.
|
| 18 |
刘佳明, 刘伟, 徐达, 等. RAS基因突变对结直肠癌肝转移患者肝切除术后预后的影响 [J]. 中华肝胆外科杂志, 2020, 26(1): 1-5.
|
| 19 |
Selcukbiricik F, Bilici A, Tural D, et al. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? [J]. Tumour Biol, 2013, 34(4): 2233-2239.
|
| 20 |
郭源, 张龙, 张舜, 等. 结直肠癌错配修复蛋白表达及微卫星不稳定与TNM分期的相关性 [J]. 肿瘤研究与临床, 2019, 31(6): 376-380.
|
| 21 |
柴华, 金翔宇, 金霞云, 等. 微卫星不稳定、HER2与结直肠癌恶性程度相关 [J]. 基础医学与临床, 2019, 39(2): 218-221.
|
| 22 |
Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H) [J]. Ann Oncol, 2014, 25(5): 1032-1038.
|
| 23 |
Jiang Y, Zhang C, Chen K, et al. The clinical significance of DC-SIGN and DC-SIGNR, which are novel markers expressed in human colon cancer [J]. PLoS One, 2014, 9(12): e114748.
|
| 24 |
于海涛, 曲义坤, 于海波, 等. 外周血内基质金属蛋白酶-7, 糖类抗原242在直肠癌诊断及术后评估中的价值 [J]. 中国老年学杂志, 2018, 38(9): 55-57.
|
| 25 |
马顺茂, 贾漪涛, 刘红磊, 等. 结直肠癌组织中基质金属蛋白酶-10的表达及临床意义 [J]. 中国全科医学, 2011, 14(2): 161-163.
|
| 26 |
刘爽, 赵冬雪. 基质金属蛋白酶12的研究进展 [J]. 医学综述, 2018, 24(14): 2781-2786.
|
| 27 |
Klupp F, Neumann L, Kahlert C, et al. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients [J]. BMC Cancer, 2016, 16: 494.
|
| 28 |
Takiyyuddin MA, Cervenka JH, Sullivan PA, et al. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? [J]. Circulation, 1990, 81(1): 185-195.
|
| 29 |
Zhang X, Zhang H, Shen B, Sun XF. Chromogranin-A expression as a novel biomarker for early diagnosis of colon cancer patients [J]. Int J Mol Sci, 2019, 20(12): 2919.
|
| 30 |
陈静静, 门万琪, 成祖群, 等. 结肠癌患者血清IL-6, CEA和CA19-9联合检测的临床意义 [J]. 免疫学杂志, 2013, 29(12): 1071-1073.
|
| 31 |
李欣欣, 陈焕杰, 庄少惠, 等. 白介素-17在结肠癌中的表达及意义 [J]. 汕头大学医学院学报, 2019, 32(2): 82-85.
|
| 32 |
Hu WH, Chen HH, Yen SL, et al. Increased expression of interleukin‐23 associated with progression of colorectal cancer [J]. J Surg Oncol, 2017, 115(2): 208-212.
|
| 33 |
Zeng JC, Zhang Z, Li TY, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis [J]. Int J Clin Exp Pathol, 2013, 6(9): 1806-1816.
|
| 34 |
Chen F, Zhang F, Tan Z, et al. Interleukin-38 in colorectal cancer: a potential role in precision medicine [J]. Cancer Immunol Immunother, 2020, 69(1): 69-79.
|
| 35 |
Esmaeili M, Keshani M, Vakilian M, et al. Role of non-coding RNAs as novel biomarkers for detection of colorectal cancer progression through interaction with the cell signaling pathways [J]. Gene, 2020, 753: 144796.
|
| 36 |
Perakis SO, Thomas JE, Pichler M. Non-coding RNAs enabling prognostic stratification and prediction of therapeutic response in colorectal cancer patients [J]. Adv Exp Med Biol, 2016, 937: 183-204.
|
| 37 |
Wang L, Cho KB, Li Y, et al. Long Noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer [J]. Int J Mol Sci, 2019, 20(22): 5758.
|
| 38 |
Hao S, Yao L, Huang J, et al. Genome-wide analysis identified a number of dysregulated long noncoding RNA (lncRNA) in human pancreatic ductal adenocarcinoma [J]. Technol Cancer Res Treat, 2018, 17: 1533034617748429.
|
| 39 |
Jing H, Qu X, Liu L, Xia H, et al. A novel long noncoding RNA (lncRNA), LL22NC03-N64E9.1, promotes the proliferation of lung cancer cells and is a potential prognostic molecular biomarker for lung cancer [J]. Med Sci Monit, 2018, 24: 4317-4323.
|
| 40 |
Robbins SL, Cotran RS. Robbins and cotran pathological basis of disease (7th Edition)[M]. New York: Elsevier Saunders, 2005: 314-316.
|